시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 주의력 결핍 과잉행동장애(ADHD) 치료제 시장 보고서(2025년)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Global Market Report 2025
상품코드 : 1681827
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,496,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,390,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,284,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

주의력 결핍 과잉행동장애(ADHD) 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2029년까지 CAGR 5.2%로 성장할 전망이며, 172억 5,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 유전자 연구 및 개별화 의료, 정신건강 의식 고조, 세계적 및 국가적 정신건강 이니셔티브, 원격의료 확대, 행동요법의 통합 등에 기인할 것으로 보입니다. 예측 기간 주요 동향에는 치료 기술 혁신, 연구 개발 이니셔티브, 디지털 치료 통합, 정밀 의료 접근 방식, 약물 전달 시스템 혁신 등이 있습니다.

주의력 결핍 과잉행동장애의 유병률 증가는 주의력 결핍 과잉행동장애(ADHD) 치료제 시장의 향후 성장을 가속할 것으로 예상됩니다. 주의력결핍 과잉행동장애(ADHD) 유병률 상승이란 이 신경발달 장애로 진단되는 개인의 수가 시간이 지남에 따라 증가하고 있음을 의미합니다. ADHS 치료제는 이 질환의 다면적인 성질에 대처하여 ADHD에 걸린 사람의 증상관리, 기능장애, 삶의 질, 전체적인 행복 개선을 목표로 합니다. 예를 들어 2023년 1월 미국 뉴스출판사 가디언이 발표한 보고에 따르면 2022년 ADHD로 처방된 환자는 17만 명으로 추정되며 2021년 같은 시기 처방된 환자 14만 1,000명에서 20.4% 증가했습니다. 따라서 ADHD의 유병률 증가가 주의력결핍 과잉행동장애(ADHD) 치료 시장의 성장을 촉진하고 있습니다.

주의력 결핍 과잉행동장애(ADHD) 치료제 시장에서 사업을 전개하는 주요 기업은 디지털 솔루션 수요 증가와 원격 의료 수요 증가에 대응하기 위해 ADHD용 디지털 치료제의 시판약(OTC)판 Endeavor 등 디지털 선진 제품의 개발에 주력하고 있습니다. 디지털 치료제란, 의학적 질환이나 질병을 예방, 관리, 치료하기 위한 첨단 소프트웨어 프로그램에 의한 에비던스에 근거한 치료 개입입니다. 이러한 개입은 단독으로 혹은 기존의 치료와 병용할 수 있도록 설계되어 있습니다. 예를 들면, 미국의 디지털 헬스 기업인 아키리는, 2023년 6월, 주의력 결핍 과잉행동장애(ADHD)의 성인을 대상으로, 비디오 게임을 기반으로 한 디지털 치료제의 일반용 의약품(OTC) 버전을 발매했습니다. OTC판 '엔데버 OTC'는 주의력, 시간관리, 정리정돈의 기술을 향상시키도록 설계되어 있습니다. 또 이번 움직임은 아키리의 FDA 인가 처방전 비디오게임 치료제 엔데보 Rx가 ADHD 어린이용으로 성공한 데 이은 것입니다. OTC 버전은 ADHD 증상을 관리하기 위한 비약물 치료 선택지를 성인에게 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD.

The main types of drugs in attention deficit hyperactivity disorder (ADHD) therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain chemicals in the brain, helping improve attention and focus. It includes various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy, and is adapted for different age groups, including pediatric, adolescent, and adult, and distributed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce.

The main types of drugs in attention deficit hyperactivity disorder (ADHD) therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain chemicals in the brain, helping improve attention and focus. It includes various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy, and is adapted for different age groups, including pediatric, adolescent, and adult, and distributed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce.

The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $13.21 billion in 2024 to $14.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to diagnostic awareness and screening programs, rising incidence of ADHD, advancements in treatment modalities, healthcare infrastructure development, and health insurance coverage expansion.

The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $17.25 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to genetic research and personalized medicine, increasing mental health awareness, global and national mental health initiatives, telehealth expansion, integration of behavioral therapies. Major trends in the forecast period include technological innovations in treatment, research and development initiatives, digital therapeutics integration, precision medicine approaches, innovations in drug delivery systems.

The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in January 2023, according to reports published by the Guardian, a US-based news publishing company, an estimated 170,000 identified patients were prescribed for ADHD in 2022, a 20.4% increase from the 141,000 identified patients during the same period in 2021. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.

Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.

In March 2022, Optum Inc., a US-based healthcare services provider company, acquired Refresh Mental Health for $700 million. This acquisition will enhance Optum's outpatient mental and behavioral health service provider position. It will expand its effective behavioral care to patients and drive deeper medical and behavioral health care integration. Refresh Mental Health is a US-based company offering various mental and behavioral health services, including ADHD psychiatry and therapy.

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical's, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on attention deficit hyperactivity disorder (adhd) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for attention deficit hyperactivity disorder (adhd) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The attention deficit hyperactivity disorder (adhd) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Characteristics

3. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends And Strategies

4. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Analysis And Strategic Analysis Framework

6. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segmentation

7. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

9. China Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

10. India Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

11. Japan Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

12. Australia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

13. Indonesia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

14. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

15. Western Europe Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

16. UK Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

17. Germany Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

18. France Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

19. Italy Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

20. Spain Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

21. Eastern Europe Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

22. Russia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

23. North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

24. USA Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

25. Canada Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

26. South America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

27. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

28. Middle East Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

29. Africa Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

30. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Competitive Landscape And Company Profiles

31. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Other Major And Innovative Companies

32. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

34. Recent Developments In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

35. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기